Efficacy and safety of Sangbaipi Decoction in patients with acute exacerbation of chronic obstructive pulmonary disease

Abstract

Background: Chinese medicine Sangbaipi decoction is extensively applied to the therapy of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in China. However, owing to the low quality, small sample size, and methodological heterogeneity of these studies, this conclusion is not convincing. Consequently, it is necessary to systematically evaluate the clinical efficacy and safety of Sangbaipi Decoction in the treatment of AECOPD patients, and provide high-quality evidence for its clinical application. Methods: We will follow the preferred reporting items for systematic review and meta-analysis (PRISMA) for reporting the results of the review in this study. We will utilize the Review Manage software V5.3.0 (The Nordic Cochrane Center, The Cochrane Collaboration, 2014, Copenhagen, Denmark) to assess the risk of bias and visualize the results. We will use Stata software (version 15.0, StataCorp, College Station, TX) to perform the meta-analysis. Ethics and dissemination: This study is a systematic review and meta-analysis protocol of Sangbaipi decoction on AECOPD, participants were not recruited and data were not collected from participants, so ethical ratification is not required. Results: This study will provide high-quality synthesis of the effectiveness and safety of Sangbaipi decoction for AECOPD. Upon completion, the results will be submitted to a peer-reviewed journal. Conclusion: The efficacy and safety assessment of Sangbaipi decoction for AECOPD will be supported by this protocol. Registration number: PROSPERO CRD 42019138405.

Chinese medicine Phragmites communis (Lu Gen) for acute respiratory tract infections: a systematic review and meta-analysis of randomized controlled trials

“…A total of 421 studies were excluded for not meeting the inclusion criteria as they were not RCTs (n = 8), did not involve adults with ARTIs (n = 159), did not contain Lu Gen in the intervention group or contained TCM in the control group (n = 253), or had wrong data (n = 1). Finally, 42 trials involving 6,879 participants, published between 2006 and 2022, met the inclusion criteria and were included for meta-analysis (Zhang, 2006;Wang, 2007;Guo, 2009;Huai, 2009;Shi et al, 2010;Wang, 2010;Hui et al, 2012;Wong et al, 2012;Xue, 2012;Xu and Zhi, 2013;Zhou, 2013;Sun, 2014a;Sun, 2014b;Chen, 2014;Pan, 2014;Wei, 2014;Xu, 2014;Chang, 2016;Chen and Li, 2016;Cheng et al, 2016;Zhang, 2016;Zhang et al, 2016;Guo and Xie, 2017;Xue et al, 2017;Zhang, 2017;Bi et al, 2019;Hu, 2019;Luo and Zhong, 2019;Yang, 2019;Zheng, 2019;Hong et al, 2020;Li, 2020;Wang, 2020;Ye et al, 2020;Song, 2021;Zhou and Qu, 2021;Li et al, 2022a;Li et al, 2022b;Li et al, 2022c;Li et al, 2022d;…”

“…The included studies were conducted in patients with AECOPD (n = 13) (Song, 2021;Li, 2020;Zhang, 2017;Wei, 2014;Li et al, 2022a;Li et al, 2022b;Zheng, 2019;Zhang et al, 2016;Chen, 2014;Shi et al, 2010;Hong et al, 2020;Wang, 2020;Chang, 2016), acute bronchitis (n = 2) (Bi et al, 2019;Ye et al, 2020), influenza (n = 6) (Wang, 2007;Hui et al, 2012;Sun, 2014b;Zong and Chen, 2020;Li et al, 2022c;Li et al, 2022d), acute upper respiratory infections (n = 21) (Zhang, 2006;Guo, 2009;Huai, 2009;Wang, 2010;Wong et al, 2012;Xue, 2012;Xu and Zhi, 2013;Zhou, 2013;Sun, 2014a;Pan, 2014;Xu, 2014;Chen and Li, 2016;Cheng et al, 2016;Zhang, 2016;Guo and Xie, 2017;Xue et al, 2017;Hu, 2019;Luo and Zhong, 2019;Yang, 2019;Zhou and Qu, 2021;Li et al, 2022c), and acute respiratory infection with fever…”

“…Frontiers in Pharmacology frontiersin.org 2010; Wang, 2010;Xue, 2012;Chen, 2014;Wei, 2014;Xu, 2014;Chen and Li, 2016;Bi et al, 2019;Hu, 2019;Luo and Zhong, 2019;Zhou and Qu, 2021) included patients with the onset of illness within 3-23 days, and 13 trials (Hui et al, 2012;Chang, 2016;Zhang, 2016;Zhang et al, 2016;Guo and Xie, 2017;Zhang, 2017;Zheng, 2019;Hong et al, 2020;Li, 2020;Wang, 2020;Ye et al, 2020;Song, 2021;Li et al, 2022b) did not report the details of onset.…”

Analysis of the Clinical Efficacy and Molecular Mechanism of Xuefu Zhuyu Decoction in the Treatment of COPD Based on Meta-Analysis and Network Pharmacology

“…For overall bias, a total of 12 included studies were assessed as some concerns, and another 2 trials were judged as high risk. The poor results of the overall risk of bias assessment were mainly due to the absence of random assignment and allocation concealment details in the original studies, especially in the clinical trials conducted by Li et al [ 42 ] and Liu et al [ 45 ], which suggested the low quality of original studies.…”

Guidelines of integrated Chinese and western medicine for diagnosis and treatment of chronic obstructive pulmonary disease (2022)

“…TCM syndrome of retention of heat‐phlegm in the lung was the most common for AECOPD patients combined with bacterial infection. For patients with such syndrome, it was recommended, on the basis of the standardized treatment of Western medicine, to give heat‐clearing and phlegm‐reducing Chinese medicines as appropriate, which could reduce the use of antibiotics to a certain extent 63,64 . However, there was a lack of high quality of evidence, and further high‐level evidence needs to be provided.…”